References

[1] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al. Heart disease and stroke statistics-2020 Update: a report from the American Heart Association. Circulation 2020;141 :e139-e596.
[2] Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77 :450-500.
[3] Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2021;43 :561-632.
[4] Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg 2015;149 :1262-9.
[5] Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, Mirza A, Loardi C, May MA et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg 2015;99 :831-7.
[6] Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF et al. Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac Surg 2015;99 :1239-47.
[7] Anselmi A, Ruggieri VG, Belhaj Soulami R, Flécher E, Langanay T, Corbineau H et al. Hemodynamic results and mid-term follow-up of 850 19 to 23 mm Perimount Magna Ease valves. Thorac Cardiovasc Surg 2019;67 :274-81.
[8] Banbury MK, Cosgrove DM, 3rd, Thomas JD, Blackstone EH, Rajeswaran J, Okies JE et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 2002;73 :1460-5.
[9] Carpentier A. From valvular xenograft to valvular bioprosthesis (1965-1977). Med Instrum 1977;11 :98-101.
[10] Carpentier A, Dubost C, Lane E, Nashef A, Carpentier S, Relland J et al. Continuing improvements in valvular bioprostheses. J Thorac Cardiovasc Surg 1982;83 :27-42.
[11] Thorp SD, Khazaal J, Yu G, Parker JL, Timek TA. Magna ease bioprosthetic aortic valve: mid-term haemodynamic outcomes in 1126 patients. Interact Cardiovasc Thorac Surg 2021;32 :839-45.
[12] Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 2008;135 :732-8.
[13] Piperata A, Fiocco A, Cavicchiolo A, Ponzoni M, Pesce R, Gemelli M et al. Carpentier-Edwards Magna Ease bioprosthesis: a multicentre clinical experience and 12-year durability. Eur J Cardiothorac Surg 2022;61 :888-96.
[14] Goldman S, Cheung A, Bavaria JE, Petracek MR, Groh MA, Schaff HV. Midterm, multicenter clinical and hemodynamic results for the Trifecta aortic pericardial valve. J Thorac Cardiovasc Surg 2017;153 :561-9 e2.
[15] Lehmann S, Jawad K, Dieterlen MT, Hoyer A, Garbade J, Davierwala P et al. Durability and clinical experience using a bovine pericardial prosthetic aortic valve. J Thorac Cardiovasc Surg 2021;161 :1742-9.
[16] Biancari F, Valtola A, Juvonen T, Husso A, Dahlbacka S, Laakso T et al. Trifecta versus PERIMOUNT Magna Ease aortic valve prostheses. Ann Thorac Surg 2020;110 :879-88.
[17] Yang B, Makkinejad A, Fukuhara S, Clemence J, Jr., Farhat L, Malik A et al. Stentless Versus Stented Aortic Valve Replacement for Aortic Stenosis. Ann Thorac Surg 2022.
[18] Yount KW, Hawkins RB, Mehaffey JH, Teman NR, Yarboro LT, Kern JA et al. Aortic valve biologic protheses: A cohort comparison of premature valve failure. J Card Surg 2022.
[19] Axtell AL, Chang DC, Melnitchouk S, Jassar AS, Tolis G, Villavicencio MA et al. Early structural valve deterioration and reoperation associated with the mitroflow aortic valve. J Card Surg 2018;33 :778-86.
[20] Yanagawa B, Tam DY, Hong K, Mazine A, Bagai A, Shahbaz NKet al. Magna Ease versus Trifecta early hemodynamics: a systematic review and meta-analysis. Innovations (Phila) 2018;13 :267-72.
[21] Yongue C, Lopez DC, Soltesz EG, Roselli EE, Bakaeen FG, Gillinov AM et al. Durability and performance of 2298 Trifecta aortic valve prostheses: a propensity-matched analysis. Ann Thorac Surg 2021;111 :1198-205.
[22] Forcillo J, Pellerin M, Perrault LP, Cartier R, Bouchard D, Demers P et al. Carpentier-Edwards pericardial valve in the aortic position: 25-years experience. Ann Thorac Surg 2013;96 :486-93.
[23] Kilic A, Sultan I, Navid F, Aranda-Michel E, Chu D, Thoma Fet al. Trifecta aortic bioprosthesis: midterm results in 1,953 patients from a single center. Ann Thorac Surg 2019;107 :1356-62.
[24] Bartus K, Litwinowicz R, Bilewska A, Stapor M, Bochenek M, Rozanski J et al. Final 5-year outcomes following aortic valve replacement with a RESILIA™ tissue bioprosthesis. Eur J Cardiothorac Surg 2021;59 :434-41.
[25] Johnston DR, Griffith BP, Puskas JD, Bavaria JE, Svensson LG, Investigators CT. Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue. J Thorac Cardiovasc Surg 2020;162 :1478-85.